JP4828421B2 - 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 - Google Patents

受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 Download PDF

Info

Publication number
JP4828421B2
JP4828421B2 JP2006523384A JP2006523384A JP4828421B2 JP 4828421 B2 JP4828421 B2 JP 4828421B2 JP 2006523384 A JP2006523384 A JP 2006523384A JP 2006523384 A JP2006523384 A JP 2006523384A JP 4828421 B2 JP4828421 B2 JP 4828421B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
heterocyclyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006523384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502295A5 (enExample
JP2007502295A (ja
Inventor
ウォレス，エル
トパロブ，ジョージ
リシカトス，ジョゼフ
バックメルター，アレクサンダー
ヂャオ，チエン
Original Assignee
アレイ バイオファーマ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/642,440 external-priority patent/US7501427B2/en
Application filed by アレイ バイオファーマ、インコーポレイテッド filed Critical アレイ バイオファーマ、インコーポレイテッド
Publication of JP2007502295A publication Critical patent/JP2007502295A/ja
Publication of JP2007502295A5 publication Critical patent/JP2007502295A5/ja
Application granted granted Critical
Publication of JP4828421B2 publication Critical patent/JP4828421B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Structural Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2006523384A 2003-08-14 2004-08-10 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 Expired - Lifetime JP4828421B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/642,440 2003-08-14
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors
US55171804P 2004-03-10 2004-03-10
US60/551,718 2004-03-10
PCT/US2004/026235 WO2005016346A1 (en) 2003-08-14 2004-08-10 Quinazoline analogs as receptor tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2007502295A JP2007502295A (ja) 2007-02-08
JP2007502295A5 JP2007502295A5 (enExample) 2007-09-27
JP4828421B2 true JP4828421B2 (ja) 2011-11-30

Family

ID=34198338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523384A Expired - Lifetime JP4828421B2 (ja) 2003-08-14 2004-08-10 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体

Country Status (23)

Country Link
US (2) US7452895B2 (enExample)
EP (1) EP1660090B1 (enExample)
JP (1) JP4828421B2 (enExample)
KR (2) KR100953246B1 (enExample)
CN (3) CN103664802B (enExample)
AR (1) AR045378A1 (enExample)
AU (1) AU2004264937B2 (enExample)
BR (1) BRPI0413565B8 (enExample)
CA (1) CA2535614C (enExample)
CL (1) CL2004002066A1 (enExample)
CY (1) CY1113992T1 (enExample)
DK (1) DK1660090T3 (enExample)
ES (1) ES2399427T3 (enExample)
IL (1) IL173593A (enExample)
IS (1) IS8288A (enExample)
MX (1) MXPA06001767A (enExample)
NO (1) NO336275B1 (enExample)
NZ (1) NZ545459A (enExample)
PL (1) PL1660090T3 (enExample)
PT (1) PT1660090E (enExample)
RU (1) RU2350605C2 (enExample)
TW (1) TWI353982B (enExample)
WO (1) WO2005016346A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DK1660090T3 (da) 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
CN101356171A (zh) 2005-11-15 2009-01-28 阿雷生物药品公司 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物
RS56608B1 (sr) 2011-10-14 2018-02-28 Array Biopharma Inc Čvrsta disperzija
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
EP3842044A1 (en) 2012-03-23 2021-06-30 Array Biopharma, Inc. Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
KR20180048804A (ko) 2015-09-04 2018-05-10 아슬란 파마슈티컬스 피티이 엘티디 바리티닙 및 항암제를 포함하는 병용 요법
EP3445366A1 (en) * 2016-04-21 2019-02-27 Aslan Pharmaceuticals PTE Limited Method of treating liver cancer
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CN106317040A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106279135A (zh) * 2016-08-09 2017-01-04 浙江医药高等专科学校 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106317039A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106349231A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106349230A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
JP7328151B2 (ja) 2017-04-28 2023-08-16 シージェン インコーポレイテッド Ｈｅｒ２陽性がんの処置
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
FI4360713T3 (fi) 2018-09-18 2024-12-27 Hoffmann La Roche Kinatsoliinijohdannaisia kasvaimia estävinä aineina
EP3864014B1 (en) * 2018-10-09 2023-07-05 ASLAN Pharmaceuticals Pte Ltd Malonate salt of varlitinib
CN111499622B (zh) * 2019-07-08 2023-06-06 山东省科学院菏泽分院 一种治疗胆管癌的药物的制备方法
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
MX2023015139A (es) 2021-06-26 2024-01-22 Array Biopharma Inc Inhibidores de mutacion de her2.
WO2023081637A1 (en) * 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
TW202345816A (zh) * 2022-03-28 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用
WO2025067396A1 (zh) * 2023-09-27 2025-04-03 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的可药用盐、其结晶形式及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536414A (ja) * 1999-02-10 2002-10-29 アストラゼネカ アクチボラグ 血管形成阻害剤としてのキナゾリン誘導体
JP2003509500A (ja) * 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ 治療用キナゾリン誘導体
WO2003040108A1 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
WO2003055491A1 (en) * 2001-12-24 2003-07-10 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5204348A (en) * 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (enExample) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP2163546B1 (en) * 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
AU719434B2 (en) 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
US6017922A (en) 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
JP3687900B2 (ja) 1998-11-19 2005-08-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー チロシンキナーゼの不可逆的阻害剤であるｎ−［４−（３−クロロ−４−フルオロフェニルアミノ）−７−（３−モルホリン−４−イルプロポキシ）キナゾリン−６−イル］アクリルアミド
KR20020002370A (ko) 1999-01-13 2002-01-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 벤조헤테로사이클 및 ｍｅｋ 억제제로서의 그의 용도
SK3832002A3 (en) 1999-09-21 2002-11-06 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
DK1257526T3 (da) 2000-02-17 2005-09-12 Bristol Myers Squibb Co Anilin-afledte ligander til thyreoidea-receptoren
DE60106022T2 (de) 2000-06-06 2006-03-09 Pfizer Products Inc., Groton Thiophenverbindungen zur verwendung als antikrebsmittel
JP4044839B2 (ja) 2000-06-22 2008-02-06 ファイザー・プロダクツ・インク 異常細胞増殖を治療するための置換２環式誘導体
MXPA02012681A (es) * 2000-06-30 2003-04-25 Glaxo Group Ltd Compuestos de sales de ditosilato de quinazolina.
WO2003015778A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003037252A2 (en) 2001-10-30 2003-05-08 Merck & Co., Inc. Tyrosine kinase inhibitors
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
KR20050122199A (ko) 2003-01-23 2005-12-28 티.케이. 시그널 리미티드 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도
PE20040945A1 (es) 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
CA2527017A1 (en) 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DK1660090T3 (da) 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
KR20060037447A (ko) 2003-08-18 2006-05-03 화이자 프로덕츠 인크. ｅｒｂＢ２ 항암제에 대한 투약 스케쥴
MXPA06005024A (es) 2003-11-06 2006-07-06 Pfizer Prod Inc Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer.
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
CN101356171A (zh) 2005-11-15 2009-01-28 阿雷生物药品公司 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536414A (ja) * 1999-02-10 2002-10-29 アストラゼネカ アクチボラグ 血管形成阻害剤としてのキナゾリン誘導体
JP2003509500A (ja) * 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ 治療用キナゾリン誘導体
WO2003040108A1 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
WO2003055491A1 (en) * 2001-12-24 2003-07-10 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases

Also Published As

Publication number Publication date
KR20100018079A (ko) 2010-02-16
CN103664802A (zh) 2014-03-26
NZ545459A (en) 2009-12-24
KR100953246B1 (ko) 2010-04-16
CN103664802B (zh) 2015-08-05
RU2006103493A (ru) 2007-09-20
AU2004264937A1 (en) 2005-02-24
KR20060064630A (ko) 2006-06-13
CA2535614C (en) 2009-12-22
BRPI0413565A (pt) 2006-10-17
CN103772373B (zh) 2017-06-09
PT1660090E (pt) 2013-01-11
EP1660090A1 (en) 2006-05-31
AU2004264937B2 (en) 2010-04-29
BRPI0413565B1 (pt) 2019-10-01
US8278314B2 (en) 2012-10-02
TWI353982B (en) 2011-12-11
AR045378A1 (es) 2005-10-26
IL173593A0 (en) 2006-07-05
IL173593A (en) 2011-11-30
US7452895B2 (en) 2008-11-18
BRPI0413565B8 (pt) 2021-05-25
DK1660090T3 (da) 2012-12-17
KR101028952B1 (ko) 2011-04-12
CN103772373A (zh) 2014-05-07
NO20061171L (no) 2006-04-10
PL1660090T3 (pl) 2013-04-30
TW200519096A (en) 2005-06-16
CN102432552B (zh) 2016-01-20
ES2399427T3 (es) 2013-04-01
JP2007502295A (ja) 2007-02-08
RU2350605C2 (ru) 2009-03-27
EP1660090B1 (en) 2012-11-21
NO336275B1 (no) 2015-07-06
CL2004002066A1 (es) 2005-06-03
HK1085400A1 (en) 2006-08-25
US20050043334A1 (en) 2005-02-24
CY1113992T1 (el) 2016-07-27
MXPA06001767A (es) 2006-05-12
WO2005016346A1 (en) 2005-02-24
CA2535614A1 (en) 2005-02-24
US20090048279A1 (en) 2009-02-19
EP1660090A4 (en) 2008-12-03
IS8288A (is) 2006-02-07
CN102432552A (zh) 2012-05-02

Similar Documents

Publication Publication Date Title
JP4828421B2 (ja) 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US11174273B2 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
DE60126997T2 (de) Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
JP5770281B2 (ja) ｃ−ＭＥＴチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体
RU2378267C2 (ru) Новые пиримидинамидные производные и их применение
BG64825B1 (bg) Бициклични хетероароматни съединения, метод за получаването им, фармацевтични състави и използването им като протеин тирозин киназни инхибитори
MX2010011097A (es) Compuesto de aciltiourea o sal del mismo, y uso del mismo.
JP7190755B2 (ja) オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用
HK1162929A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
HK1085400B (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
JP2018526411A (ja) Ｔｒｐｍ８拮抗剤としてのイミダゾリノン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100928

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110830

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110914

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140922

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4828421

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term